Amneal Pharmaceuticals, Inc. 8-K

What Happened Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K on May 7, 2026 reporting the results of its 2026 Annual Meeting of Stockholders held May 6, 2026. All director nominees were elected and the other proposals were approved by the stockholders: the non‑binding advisory vote on executive compensation ("say‑on‑pay") passed, and Ernst & Young LLP was ratified as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• All listed director nominees were elected; vote tallies included (For / Against / Abstain / Broker Non‑Votes): e.g., Gautam Patel 270,643,127 / 1,042,157 / 39,489 / 21,948,638; Chintu and Chirag Patel each received ~270.36M For votes; Paul Meister received 237,733,309 For votes (see filing for full breakdown).
• Say‑on‑pay (Proposal 2) passed: 269,089,785 For, 2,577,481 Against, 57,507 Abstain; 21,948,638 broker non‑votes.
• Auditor ratification (Proposal 3) approved overwhelmingly: 293,211,820 For, 409,435 Against, 52,156 Abstain; 0 broker non‑votes.
• Filing date: May 7, 2026; Annual Meeting date: May 6, 2026.

Why It Matters These results confirm board continuity and shareholder support for Amneal’s current leadership and executive compensation program. The strong ratification of Ernst & Young LLP ensures continuity of the company’s external audit for 2026. Retail investors may view the affirmative say‑on‑pay vote and broad director approvals as indicators of governance stability; broker non‑votes (21.95M) reflect shares held by brokers that did not vote on certain matters.